Form 8-K - Current report:
SEC Accession No. 0001279569-24-001480
Filing Date
2024-12-16
Accepted
2024-12-13 21:32:17
Documents
13
Period of Report
2024-12-12
Items
Item 1.02: Termination of a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 FORM 8-K form8k.htm   iXBRL 8-K 24924
  Complete submission text file 0001279569-24-001480.txt   199914

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA epix-20241212.xsd EX-101.SCH 3021
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE epix-20241212_lab.xml EX-101.LAB 34240
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE epix-20241212_pre.xml EX-101.PRE 22363
16 EXTRACTED XBRL INSTANCE DOCUMENT form8k_htm.xml XML 3772
Mailing Address SUITE 720 999 WEST BROADWAY VANCOUVER A1 V5Z 1K5
Business Address SUITE 720 999 WEST BROADWAY VANCOUVER A1 V5Z 1K5 (778) 331-0962
ESSA Pharma Inc. (Filer) CIK: 0001633932 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-37410 | Film No.: 241549957
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)